AstraZeneca, Eccogene Enter Exclusive License Agreement for GLP-1 Drug

Gains global rights to Eccogene’s next-gen oral GLP-1 receptor agonist ECC5004 for $185 million upfront and as much as an additional $1.8 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca and Eccogene entered into an exclusive license agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions.   Preliminary Phase I trials have shown a differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo.   Eccogene will receive $185 mil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters